Bicycle Therapeutics (BCYC) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bicycle Therapeutics (BCYC) has outperformed Upstream Bio (UPB) over the past year, losing 53.9% versus a loss of 76.0%. Bicycle Therapeutics is the larger company by market cap ($266.7 million vs $249.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCYC | UPB |
|---|---|---|
| Share price | $3.81 | $4.55 |
| Market cap | $266.67M | $249.21M |
| 1-day change | +2.14% | -1.30% |
| YTD return | -46.19% | -83.24% |
| 1-year return | -53.87% | -75.95% |
| 5-year return | -93.57% | — |
| EPS (TTM) | $-2.80 | $-2.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.10 | $33.68 |
| 52-week low | $3.33 | $4.37 |
| Distance from 52-week high | -58.13% | -86.49% |
| Analyst consensus | none | none |
| Avg. price target upside | +149.34% | +584.40% |
| Average volume | 387.29K | 610.08K |
| Shares outstanding | 50.55M | 54.77M |
| Employees | 288 | 75 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCYC has outperformed UPB by 22.1 percentage points over the past year.
About Bicycle Therapeutics
BCYC stock →Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
Healthcare · Biotechnology · 288 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Healthcare · Biotechnology · 75 employees
BCYC vs UPB FAQ
Which is bigger, Bicycle Therapeutics or Upstream Bio?
Bicycle Therapeutics (BCYC) is larger, with a market capitalization of $266.67M compared with $249.21M for Upstream Bio (UPB).
Which stock has performed better over the past year, BCYC or UPB?
BCYC returned -53.87% over the past 12 months, compared with -75.95% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are Bicycle Therapeutics and Upstream Bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.